Pfizer Inc (PFE): Today's Featured Drugs Winner

Pfizer ( PFE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.2%. By the end of trading, Pfizer rose $0.32 (1.2%) to $27.97 on light volume. Throughout the day, 36,448,664 shares of Pfizer exchanged hands as compared to its average daily volume of 63,638,100 shares. The stock ranged in a price between $27.78-$28.10 after having opened the day at $28.05 as compared to the previous trading day's close of $27.65. Other companies within the Drugs industry that increased today were: Merus Labs International ( MSLI), up 18.7%, Prima Biomed ( PBMD), up 16.7%, Oramed Pharmaceuticals ( ORMP), up 16.1% and Celldex Therapeutics ( CLDX), up 14.1%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $195.7 billion and is part of the health care sector. Shares are up 10.4% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Mast Therapeutics ( MSTX), down 40.0%, Cardiome Pharma Corporation ( CRME), down 6.5%, Hemispherx Biopharma ( HEB), down 6.2% and Cormedix ( CRMD), down 5.6% , were all laggards within the drugs industry with Infinity Pharmaceuticals ( INFI) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux